Nutriband Inc

Chart & Performance

D1W1MN

P/E

—

P/S

18.44

EPS

—

Div Yield, %

—

Shrs. gr., 5y

11.57%

Rev. gr., 5y

16.63%

Revenues

-4.83%

Net income

-8m

L-21.50%

CFO

-5m

L+10.97%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

Nutriband Inc. is a pharmaceutical company dedicated to advancing a diverse pipeline of transdermal drug products. Foremost among its developmental initiatives is an abuse-deterrent fentanyl transdermal system. This innovative patch aims to provide both healthcare providers and patients with an extended-release fentanyl solution for the effective management of chronic pain. Beyond its core transdermal portfolio, Nutriband Inc. also holds a licensing agreement with Rambam Med-Tech Ltd. for the development of RAMBAM Closed System Transfer Devices. Established in 2016, the company maintains its corporate headquarters in Orlando, Florida.

URL

https://nutriband.com/

IPO date

Jun 20, 2017

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2026‑01	2025‑01	2024‑01	2023‑01	2022‑01	2021‑01	2020‑01	2019‑01	2018‑01	2017‑01
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT